Take-home messages from 6-month data for overactive bladder device

In this video, Colin Goudelocke, MD, shares the take-home messages from the Neurourology and Urodynamics study, “Evaluation of clinical performance and safety for the rechargeable InterStim Micro device in overactive bladder subjects: 6-month results from the global postmarket ELITE study.” Goudelocke is a urologist with Ochsner Health Center in New Orleans, Louisiana.

Transcription:

The first thing I'd say is that we know these devices are safe. Anytime you have a new device, a new drug, a new treatment, particularly when we have comparable older treatments, it's really important to make sure that we're putting in a safe device. "First, do no harm." That's the most important take-home message to me because if the device isn't safe, it really doesn't matter how efficacious it is. The other take-home message is that it does look at least at 6 months, at this intermediate snapshot, that the efficacy data that we saw early on at 3 months is sustained, and it's very comparable to what we see in other devices. So when we talk about a smaller size, one of the things that we don't have to trade is efficacy. The other take-home message is for those of us that have a perception of a decrease in effectiveness over time, or maybe even a decrease in patient's perception of effectiveness over time, at least at 6 months, we're not seeing this in the overactive bladder and urgency incontinence arms, which is really exciting to me as someone who takes care of these patients every day. The last take-home message is that we really need to get more information about who's going to benefit most from these smaller devices. Is it men, is it women, is it elderly patients? Is it younger patients? Is it patients with urgency incontinence vs fecal incontinence? That's going to be really important to look at over the next year and a half to 2 years.

This transcription was edited for clarity.